Pain medicine and bone mets - page 5
I have a patient with lung cancer that has spread to spine. Pain is horrendous, any suggestions. Currently on Fentanly 100mcg, Percocet 10 (2) every 4hrs and Roxanol every hr as needed. Thanks for... Read More
Feb 19, '14I'm pretty sure the poster meant morphine sulfate IMMEDIATE RELEASE Q4H PRN. ....bc we certainly wouldn't be dosing an extended release morphine tablet PRN......
Feb 23, '14Kudos to you wanting more knowledge/advice to seek effective pain relief for your patient. Each patient needs a personal plan to control cancer pain as each person's diagnosis, cancer stage, response to pain, and personal likes and dislikes are different. Type of cancer/site origin + metastatic area greatly influences metastatic pain management.
The Management of Pain in Metastatic Bone Disease - Medscape
Step 1 consists of nonopioid analgesics when pain is mild. Nonsteroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors, acetaminophen, adjuvants, and topical analgesic compounds comprise this group. Much controversy has revolved around the safety of NSAIDs; currently, their use is advised with caution, particularly in the elderly.  Adjuvants typically refer to drugs that, although are not analgesics per se, can be used for this indication in special circumstances. Several antiepileptics and antidepressants are first-line therapies in the management of neuropathic pain. The most commonly used agents include gabapentin, pregabalin, and tricyclic antidepressants (eg, amitriptyline, nortriptyline).
Step 2 introduces weak opioids such as hydrocodone, codeine, and low-dose oxycodone for pain that is mild to moderate. Other μ receptor agonists with dual mechanisms of action include tramadol and, most recently, tapentadol. These drugs reduce much of the side effects profile of pure opioids and have added effects on neuropathic pain. Propoxyphene (Darvocet, Darvon) has been taken off the market due to concerns of cardiac arrhythmias.
Step 3 consists of stronger opioids such as morphine, hydromorphone, fentanyl, high-dose oxycodone, meperidine, and methadone.
For patients with chronic cancer pain, a combination of long- and short-acting opioids is recommended. The long-acting opioids, whether they are pharmacologically long-acting (such as methadone or levorphanol) or pharmaceutically long-acting (a slow-release delivery system such as extended-release morphine, oxycodone, oxymorphone or hydromorphone), are used for the chronic baseline cancer pain. The shortacting opioids that require repetitive dosing are used for the acute pain.
Regarding breakthrough pain, which is defined as an abrupt, short-lived, and intense flare of pain in the setting of chronic stable pain managed with opioids,  there is an increasing trend to the use of transmucosal lipophilic drugs (eg, oral transmucosal fentanyl citrate, fentanyl buccal tablets, sublingual fentanyl, intranasal fentanyl spray, fentanyl pectin nasal spray, fentanyl buccal soluble film) due to the rapid effect of these drugs, which is clinically observable 10 to 15 minutes after administration. [28,29] Breakthrough pain has been reported to occur in 50% to 70% of cancer patients.  Patients with pain located in the spine, back, and pelvis may be at risk for resistant breakthrough pain.  Breakthrough pain can be categorized as somatic, visceral, or mixed, and also as idiopathic (spontaneous), incidental, and end-of-dose failure (when the pharmacokinetics of the analgesic do not match the patient's dosing schedule)... 
...Tumors in which hormonal therapy is of proven benefit include breast, prostate, and endometrial cancers. [35–37] ...
I've seen breast CA with mets to bones respond to this along with palliative radiation.
Nonsurgical Treatments for Metastatic Cancer in Bones - SIR
Pain Management at the End of Life - Medscape Education
Therapy of Metastatic Bone Pain* - Journal of Nuclear MedicineLast edit by NRSKarenRN on Feb 27, '14